Adequate Provision: The Broadcast Drug Ad Option in 21 CFR 202.1

Adequate provision is the option in 21 CFR 202.1(e)(1)(i)(B) that lets a prescription drug ad broadcast on radio, television or telephone systems leave out the brief summary of side effects and contraindications, if the company makes adequate provision for the approved or permitted labeling to be disseminated in connection with the broadcast. In practice the ad carries a short major statement of risks and tells the audience where to get the full labeling.

FDA said in 2025 that it would remove the option. Its 2026 Unified Agenda lists a proposed rule for December 2026. The full analysis has the timeline and the letter data.

Three terms in 21 CFR 202.1(e)(1)

Section 502(n) of the FD&C Act (21 U.S.C. 352(n)) requires a brief summary "as shall be required in regulations". It also requires that, in a consumer TV or radio ad that states the drug name and its conditions of use, the major statement be "presented in a clear, conspicuous, and neutral manner". The adequate provision language is in the regulation, not the statute.

Print and broadcast

Paragraph (e)(1) requires every prescription drug ad to carry the brief summary. Paragraph (e)(1)(i) then gives broadcast ads the choice between a brief summary and adequate provision. The phrase appears nowhere else in 202.1, so a print ad has no such option. FDA's 1999 guidance says the same: "Print advertisements must include the brief summary".

Paragraph (e)(1)(ii) adds standards for consumer TV and radio ads. The major statement must be in consumer-friendly language, its audio must be at least as understandable as the rest of the ad, and in TV format it must appear in audio and text together (dual modality) and be easy to read. During it, the ad cannot include audio or visual elements likely to interfere with comprehension. These standards govern how the major statement is shown. They did not change what it says, and they do not touch adequate provision. FDA's Q&A guidance on the 2023 rule says so.

FDA has a draft guidance on internet and social media platforms with character limits (posted June 2014). This page does not cover it.

How a broadcast ad makes adequate provision

The regulation does not say how. FDA's 1999 guidance "Consumer-Directed Broadcast Advertisements" describes one acceptable approach with four parts:

1. A toll-free number in the ad, where the caller can have the approved labeling mailed or read aloud.
2. A reference in the ad to a mechanism for people with limited access to the Internet or who prefer privacy, such as a print ad appearing at the same time.
3. A web address that gives access to the labeling.
4. A statement that pharmacists, physicians or other health care providers can give more information.

The approach presumes the ad is not false or misleading, presents fair balance, and has a thorough major statement in consumer-friendly language. The guidance does not bind FDA or the public.

History

• 1962. Section 502(n) enacted. FDA's 2023 final rule notes that a regulation requiring risk information in prescription drug ads followed in 1963 (28 FR 6375).
• 1969. Regulations address a statement of major side effects in TV and radio ads (34 FR 7802). Both are as recounted in 88 FR 80958.
• 12 August 1997. Draft guidance on consumer-directed broadcast ads (62 FR 43171). The notice describes adequate provision as already part of 202.1(e)(1).
• 9 August 1999. Final guidance (64 FR 43197).
• 27 September 2007. The Food and Drug Administration Amendments Act adds the clear, conspicuous and neutral requirement to section 502(n).
• 21 November 2023. Final rule adds 202.1(e)(1)(ii), effective 20 May 2024 with compliance by 20 November 2024.
• 9 September 2025. A presidential memorandum and FDA's press release announce rulemaking to "close the 'adequate provision' loophole created in 1997".
• 2026. The Unified Agenda lists RIN 0910-AJ14, "Transparency in Direct-to-Consumer Advertising", with an NPRM planned for December 2026.

FDA's press release dates the loophole to 1997 and its Unified Agenda entry dates it to the 1999 guidance. The 1997 draft and the 1999 final guidance describe the same approach.

Where it stands

The Unified Agenda entry says the rule "will revise 21 CFR 202.1 to eliminate the option" for broadcast ads to meet the brief summary requirement through another source. It is marked economically significant and major. As of 9 November 2026 no proposed text had been published. The scope, the content of the in-ad summary, the compliance date and the comment period are unknown. Law firms expect legal challenges. Their views are in the analysis post, which will be updated when the proposal appears.

In MLR review

Reviewers of broadcast creative check the major statement against 202.1(e)(1)(ii) and confirm that the adequate provision elements the ad relies on are live and current: the number, the web address, the print reference. In FDA's published untitled letters, the phrase is rare. One of 120 letters, an Eli Lilly letter on Emgality TV ads from December 2021, says the ads "fail to either provide adequate provision or a brief summary". The 2025 and 2026 letters about TV ads instead describe how the major statement is shown. The OPDP letter search lets you read them. Advertisements go to FDA at first publication on Form FDA 2253. See MLR review for the process around these checks.